These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 26964144)

  • 41. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].
    Schreiber S
    Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilars: clinical interpretation and implications for drug development.
    Mysler E
    Curr Rheumatol Rep; 2015 Feb; 17(2):8. PubMed ID: 25618574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching to biosimilars in the treatment of rheumatic diseases.
    Yoo DH; Choe JY; Shim SC; Suh CH
    Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
    Kim WS; Ogura M; Kwon HC; Choi D
    Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Biosimilars in rheumatology. Development and results of clinical trials].
    Alten R
    Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilars vs originators: Are they the same?
    Sarzi-Puttini P; Marotto D; Caporali R; Galeazzi M; Atzeni F; Hamar A; Soós B; Szekanecz Z
    Autoimmun Rev; 2019 Dec; 18(12):102404. PubMed ID: 31639517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
    Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
    Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges for biosimilars: focus on rheumatoid arthritis.
    Akram MS; Pery N; Butler L; Shafiq MI; Batool N; Rehman MFU; Grahame-Dunn LG; Yetisen AK
    Crit Rev Biotechnol; 2021 Feb; 41(1):121-153. PubMed ID: 33040628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Revised version of the statement by the DGRh on biosimilars-update 2017].
    Braun J; Lorenz HM; Müller-Ladner U; Schneider M; Schulze-Koops H; Specker C; Strangfeld A; Wagner U; Dörner T
    Z Rheumatol; 2018 Feb; 77(1):81-90. PubMed ID: 29383440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.